446eP PIV score as a predictor biomarker for survival in patients with extensive-stage SCLC treated with atezolizumab
The addition of Atezolizumab to platinum-based chemotherapy showed an improvement of the overall survival versus chemotherapy alone. However, studies focusing on predictive biomarkers to optimize patient selection and treatment strategies is needed. Therefore, our study aimed to evaluate the predictive impact for the pretreatment Pan-immune-inflammation value (PIV) score on survival outcomes in ES-SCLC.
Authors
- R.R. Abdel Malek
- H.Z.E. Elsandoby
- S.H. Shams Eldin
Institutions
- Cairo University (EG)
- Western Health and Social Care Trust (GB)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106760
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00